» Articles » PMID: 23299641

Do the Frequencies of Adverse Events Increase, Decrease, or Stay the Same with Long-term Use of Statins?

Overview
Publisher Springer
Date 2013 Jan 10
PMID 23299641
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Statins are widely used for their cholesterol-lowering properties and proven reduction of cardiovascular disease risk. Many patients take statins as long-term treatment for a variety of conditions without a clear-cut understanding of how treatment duration affects the frequency of adverse effects. We aimed to evaluate whether the frequencies of documented adverse events increase, decrease, or remain unchanged with long-term statin use. We reviewed the established literature to define the currently known adverse effects of statin therapy, including myopathy, central nervous system effects, and the appearance of diabetes, and the frequency of these events with long-term medication use. The frequency of adverse effects associated with long-term statin therapy appears to be low. Many patients who develop side effects from statin therapy do so relatively soon after initiation of therapy, so the frequency of side effects from statin therapy when expressed as a percentage of current users decreases over time. Nevertheless, patients may develop side effects such as muscle pain and weakness years after starting statin therapy; however, the absolute number of patients affected by statin myopathy increases with treatment duration. Also, clinical trials of statin therapy rarely exceed 5 years, so it is impossible to determine with certainty the frequency of long-term side effects with these drugs.

Citing Articles

Dual stimulus-responsive renewable nanoadsorbent for selective adsorption of low-density lipoprotein in serum.

Guo C, Jiang X, Guo X, Liu Z, Wang B, Du Y Regen Biomater. 2024; 11:rbae045.

PMID: 38845854 PMC: 11153342. DOI: 10.1093/rb/rbae045.


Facile Preparation of β-Cyclodextrin-Modified Polysulfone Membrane for Low-Density Lipoprotein Adsorption via Dopamine Self-Assembly and Schiff Base Reaction.

Fang F, Zhao H, Wang R, Chen Q, Wang Q, Zhang Q Materials (Basel). 2024; 17(5).

PMID: 38473461 PMC: 10934633. DOI: 10.3390/ma17050988.


High-dose atorvastatin therapy progressively decreases skeletal muscle mitochondrial respiratory capacity in humans.

Ryan T, Torres M, Lin C, Clark A, Brophy P, Smith C JCI Insight. 2024; 9(4).

PMID: 38385748 PMC: 10967389. DOI: 10.1172/jci.insight.174125.


Fabrication and Study of Dextran/Sulfonated Polysulfone Blend Membranes for Low-Density Lipoprotein Adsorption.

Fang F, Zhao H, Wang R, Chen Q, Wang Q, Zhang Q Materials (Basel). 2023; 16(13).

PMID: 37444954 PMC: 10342430. DOI: 10.3390/ma16134641.


Investigation of the Molecular Mechanisms Underlying the Antiatherogenic Actions of Kaempferol in Human THP-1 Macrophages.

Huwait E, Ayoub M, Karim S Int J Mol Sci. 2022; 23(13).

PMID: 35806463 PMC: 9267302. DOI: 10.3390/ijms23137461.


References
1.
Thompson P, Clarkson P, Karas R . Statin-associated myopathy. JAMA. 2003; 289(13):1681-90. DOI: 10.1001/jama.289.13.1681. View

2.
de Lemos J, Blazing M, Wiviott S, Lewis E, Fox K, White H . Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA. 2004; 292(11):1307-16. DOI: 10.1001/jama.292.11.1307. View

3.
Pasternak R, Smith Jr S, Bairey-Merz C, Grundy S, Cleeman J, Lenfant C . ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol. 2002; 40(3):567-72. DOI: 10.1016/s0735-1097(02)02030-2. View

4.
Hajjar I, Schumpert J, Hirth V, Wieland D, Eleazer G . The impact of the use of statins on the prevalence of dementia and the progression of cognitive impairment. J Gerontol A Biol Sci Med Sci. 2002; 57(7):M414-8. DOI: 10.1093/gerona/57.7.m414. View

5.
Parale G, Baheti N, Kulkarni P, Panchal N . Effects of atorvastatin on higher functions. Eur J Clin Pharmacol. 2006; 62(4):259-65. DOI: 10.1007/s00228-005-0073-z. View